Almawi_16-IC_Multiplex

Description

Serum samples from 88 treatment-naïve BC patients and 49 age-matched controls were analyzed using a 16-analyte MILLIPLEX® immuno-oncology panel. Seven immune checkpoint proteins (LAG-3, BTLA, CD80, GITRL, CTLA-4, GITR, TLR-2) showed significant differential expression between BC patients and controls. Elevated baseline TIM-3 and PD-L1 were associated with chemotherapy resistance and shorter PFS.

Steps to reproduce

Serum concentrations of BTLA, CD27, CD28, CD40, CD80/B7-1, CD86/B7-2, CTLA-4, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, TIM-3, and TLR-2 IC proteins were measured using the MILLIPLEX MAP® Human Immuno-Oncology Checkpoint Protein Magnetic Bead Panel (Millipore Sigma, Burlington, MA). This multiplex platform, combined with the Bio-Plex® 200 System and Bio-Plex Manager 5.0 software, enabled accurate, high-throughput detection across a wide dynamic range spanning three logs (0.14-12.5 pg/mL to 500-5000 pg/mL, depending on analyte).

Institutions

• Tunis El Manar University

  Tunis Governorate, Tunis

Categories

Licence